Esomeprazole - Hanmi Pharmaceutical

Drug Profile

Esomeprazole - Hanmi Pharmaceutical

Alternative Names: DR esomeprazole; Esomeprazole strontium delayed-release; Esomeprazole strontium tetrahydrate; Esomezol

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Zollinger-Ellison syndrome

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Dec 2013 Launched for Gastric ulcer in USA (PO)
  • 02 Oct 2013 The US Court of Appeals for the Federal Circuit lifts a temporary injunction against the launch of Hanmi's esomeprazole product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top